Combined transductional and transcriptional targeting improves the specificity of transgene expression in vivo

Nature Biotechnology

Volumn 19, Issue 9, 2001, Pages 838-842

  Reynolds, Paul N ^a   Nicklin, Stuart A ^b   Kaliberova, Lioudmila ^a   Boatman, Brian G ^a,c   Grizzle, William E ^a   Balyasnikova, Irina V ^d   Baker, Andrew H ^b   Danilov, Sergei M ^d   Curiel, David T ^a  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELLS; GENES; HEALTH CARE;

TARGETING;

BIOTECHNOLOGY;

DIPEPTIDYL CARBOXYPEPTIDASE; PROTEIN FIT 1; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 1; VIRUS VECTOR;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL SPECIFICITY; FEMALE; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; GENETIC TRANSCRIPTION; GENETIC TRANSDUCTION; LIVER; LUNG ENDOTHELIUM; NONHUMAN; PRIORITY JOURNAL; RAT; TRANSGENE;

ADENOVIRIDAE; ANIMALS; CELL LINE; ENDOTHELIAL GROWTH FACTORS; ENDOTHELIUM; ENDOTHELIUM, VASCULAR; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; IMMUNOHISTOCHEMISTRY; LIVER; LUCIFERASES; LUNG; LYMPHOKINES; MALE; MICE; PEPTIDYL-DIPEPTIDASE A; PROMOTER REGIONS (GENETICS); RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION; TRANSCRIPTION, GENETIC; TRANSDUCTION, GENETIC; TRANSGENES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0034861664     PISSN: 10870156     EISSN: None     Source Type: Journal    
DOI: 10.1038/nbt0901-838     Document Type: Article

References (40)

1. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. The International PPH Consortium
2. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene
3. Pulmonary hypertension: Newer concepts in diagnosis and management
4. Update on adenovirusits vectors
5. In vivo gene delivery to the pulmonary circulation in rats: Transgene distribution and vascular inflammatory response
6. The route of administration is a major determinant of the transduction efficiency of rat tissues by adenoviral recombinants
7. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5
8. HCAR and MCAR: The human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses
9. Adenovirus-mediated gene transfer of herpes simplex virus thymidine kinase in an ascites model of human breast cancer
10. Targeting adenovirus
11. Targeted gene delivery by tropism-modified adenoviral vectors
12. Genetic targeting of adenoviral vectors
13. A targetable injectable adenoviral vector for selective gene delivery to pulmonary endothelium in vivo
14. CD143 Workshop: Angiotensin-I-converting enzyme (CD143) on endothelial cells in normal and in pathological conditions
15. Pulmonary uptake and tissue selectivity of antibodies to surface endothelial antigens: Key determinants of vascular immunotargeting
16. Influence of adenoviral fiber mutations on viral encapsidation, infectivity and in vivo tropism
17. CAR binding ablation does not change biodistribution or toxicity of adenoviral vectors
18. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment
19. Gene therapy: Designer promoters for tumour targeting
20. Midkine promoter-based adenoviral vector gene delivery for pediatric solid tumors
21. Osteocalcin-directed gene therapy for prostate-cancer bone metastasis
22. Characterization of the cyclooxygenase-2 promoter in an adenoviral vector and its application for the mitigation of toxicity in suicide gene therapy of gastrointestinal cancers
23. Analysis of cell-specific promoters for viral gene therapy targeted at the vascular endothelium
24. In vivo dose threshold effect of adenovirus-mediated factor VIII gene therapy in hemophiliac mice
25. Sequestration of adenoviral vector by Kupffer cells leads to a nonlinear dose response of transduction in liver
26. Targeting adenoviral infection with basic fibroblast growth factor enhances gene delivery to vascular endothelial and smooth muscle cells
27. Targeted adenovirus gene transfer to endothelial and smooth muscle cells by using bispecific antibodies
28. Targeting an adenoviral gene vector to cytokine-activated vascular endothelium via E-selectin
29. Selective targeting of gene transfer to vascular endothelial cells by use of peptides isolated by phage display
30. Lung is the target organ for a monoclonal antibody to angiotensin- converting enzyme
31. Interaction of mAb to angiotensin-converting enzyme (ACE) with antigen in vitro and in vivo: Antibody targeting to the lung induces ACE antigenic modulation
32. Suicide gene expression induced in tumour cells transduced with recombinant adenoviral, retroviral and plasmid vectors containing the ERBB 2 promoter
33. Angiotensin converting enzyme expression in primary pulmonary hypertension
34. Expression of vascular endothelial growth factor and its receptors correlates closely with formation of the plexiform lesion in human pulmonary hypertension
35. Expression of pulmonary vascular angiotensin-converting enzyme in primary and secondary plexiform pulmonary hypertension
36. A simplified system for generating recombinant adenoviruses
37. A novel promoter for vascular endothelial growth factor receptor (flt-1) that confers endothelial-specific gene expression
38. Manipulation of adenovirus vectors
39. Enhancement of radiolabeled antibody binding and tumor localization through adenoviral transduction of the human carcinoembryonic antigen gene
40. Immune response to a carcinoembryonic antigen polynucleotide vaccine